Participated · Series D · Oct 2020

Sirnaomics is a biopharmaceutical company developing RNAi therapeutics, with a portfolio targeting oncology, anti‑fibrotic, anti‑viral and metabolic disorders. Its lead product candidates include STP705 and STP707, dual‑targeting siRNA therapeutics against TGF‑β1 and COX‑2 for local or systemic administration. The company is advancing systemic RNAi delivery platforms including siRNA‑chemodrug conjugates and proprietary GalNAc‑siRNA conjugates, and plans clinical evaluation in immune‑oncology combinations with PD‑1/PD‑L1 inhibitors. Proceeds from the announced Series E financing will fund continued development across its pipeline, advance delivery technologies, and strengthen large‑scale manufacturing capacity. Sirnaomics operates as a Delaware corporation headquartered in Gaithersburg, Maryland, with subsidiaries in Suzhou and Guangzhou, China. Sirnaomics Inc., based in Gaithersburg, Maryland, discovers and develops RNAi therapeutics. Led by Patrick Lu, PhD, Founder, President and CEO, the company focuses on oncology, anti‑fibrotic therapeutics and viral infection and has subsidiaries in Suzhou and Guangzhou, China. Its lead candidates, STP705 and STP707, are dual‑targeting siRNA therapeutics against TGF‑β1 and COX‑2 for local and systemic administrations to treat various cancers and fibrotic diseases. The company reported positive results from a Phase IIa study for treatment of Cutaneous Squamous Cell Carcinoma in‑situ and plans multiple clinical studies to further evaluate these candidates. A clinical focus will be immune‑oncological evaluation of the dual‑targeted siRNA inhibitors based on potential synergistic effects with immune checkpoint inhibitors observed in preclinical and clinical settings. Sirnaomics raised $105M in a Series D financing to fund continued development of its RNAi therapeutics across indications including cancers, fibrosis, metabolic diseases and viral infections. Sirnaomics discovers and develops RNAi therapeutics targeting cancer and fibrotic diseases. Its lead candidate, STP705, leverages a dual-targeting approach and was in a Phase II study for non-melanoma skin cancer at the time of the report. The company planned a second clinical trial for cholangiocarcinoma and hepatocellular carcinoma expected to begin in the second half of 2019. Sirnaomics said it would use proceeds from its recent financing to support its clinical programs and to advance its technology platforms. The company is led by Patrick Lu, PhD, and maintains subsidiaries in Suzhou and Guangzhou. No operating metrics were reported in the article. Sirnaomics develops RNAi therapeutics using pluripotent siRNA cocktail design and nanoparticle-enhanced delivery. The company’s lead candidate, STP705, targets TGF-β1 and COX-2 and has shown anti-fibrotic and anti-tumor activity in preclinical models. STP705 has a fully developed, validated manufacturing process and a preclinical safety profile that supports human clinical studies. STP705 is in a Phase IIa clinical study for hypertrophic scar in the U.S., and the same indication has been approved for clinical study by the Chinese FDA. The company said proceeds will expand clinical programs for its anti-fibrosis and anti-cancer RNAi therapeutics, strengthen management, and bolster pre-clinical development of new drug candidates. Sirnaomics is a Delaware corporation headquartered in Gaithersburg, Maryland, with subsidiaries in Suzhou and Guangzhou, China, and is led by Founder and CEO Dr. Patrick Y. Lu and CMO Dr. Michael Molyneaux. Sirnaomics is a Gaithersburg, Maryland–based biopharmaceutical company focused on the discovery and development of RNAi therapeutics. The company has developed a portfolio of intellectual property in areas including anti-fibrotic medicine and cancer therapeutics. Its lead product candidate, STP705, is an anti-fibrosis siRNA therapeutic that uses a dual-targeted inhibitory approach and PNP-enhanced delivery. STP705 has shown activity in animal models ranging from skin hypertrophic scar to liver and lung fibrosis. Sirnaomics intends to use new funding to advance its anti-fibrosis programs into clinical development and expected to enter a Phase I trial with STP705 in the early second half of 2016. The company also operates subsidiaries in Suzhou and Guangzhou, China.